Lexeo Reports Q2 Loss as Costs Jump 129%

Lexeo Therapeutics (NASDAQ:LXEO), a biotechnology company focused on developing gene therapies for inherited diseases, reported second quarter results on August 14, 2025. The company’s net loss per share (GAAP) was $0.60. As expected for a pre-commercial company, Lexeo reported no revenue for the period. Highlights included major regulatory strides for LX2006—its lead gene therapy candidate—and a year-over-year drop in research and development expenses (GAAP). However, costs related to general and administrative functions more than doubled (GAAP), creating a notable shift in operating expense mix. Overall, the quarter delivered clinical, regulatory, and capital progress, although spending trends will be important to monitor as the pipeline advances. Source: Analyst estimates for the quarter provided by FactSet. Lexeo Therapeutics develops genetic medicines, with its main focus on gene therapies targeting serious inherited diseases. The company uses viral and non-viral vector technologies to deliver these therapies, with programs for both cardiovascular and neurological disorders. Its most advanced product candidates target inherited heart diseases, such as Friedreich ataxia (a condition causing heart muscle disease and movement problems) and arrhythmogenic cardiomyopathy (a disorder causing abnormal heart rhythms).Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool